Terumo Corporation (TYO:4543)
Japan
· Delayed Price · Currency is JPY 2,714.00
-52.50 (-1.90%)
May 14, 2025, 9:45 AM JST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Cardiac and Vascular Company |
Log In |
Log In |
Log In |
Log In |
| Cardiac and Vascular Company Growth |
Log In |
Log In |
Log In |
Log In |
| Medical Care Solutions Company |
Log In |
Log In |
Log In |
Log In |
| Medical Care Solutions Company Growth |
Log In |
Log In |
Log In |
Log In |
| Blood and Cell Technologies Company |
Log In |
Log In |
Log In |
Log In |
| Blood and Cell Technologies Company Growth |
Log In |
Log In |
Log In |
Log In |
| Adjustments from |
Log In |
Log In |
Log In |
Log In |
| Adjustments from Growth |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Americas |
Log In |
Log In |
Log In |
Log In |
| Americas Growth |
Log In |
Log In |
Log In |
Log In |
| Europe |
Log In |
Log In |
Log In |
Log In |
| Europe Growth |
Log In |
Log In |
Log In |
Log In |
| China |
Log In |
Log In |
Log In |
Log In |
| China Growth |
Log In |
Log In |
Log In |
Log In |
| Asia and Others |
Log In |
Log In |
Log In |
Log In |
| Asia and Others Growth |
Log In |
Log In |
Log In |
Log In |
| Japan |
Log In |
Log In |
Log In |
Log In |
| Japan Growth |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Cardiac and Vascular Company Adjusted Operating Profit |
Log In |
Log In |
Log In |
Log In |
| Cardiac and Vascular Company Adjusted Operating Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Medical Care Solutions Company Adjusted Operating Profit |
Log In |
Log In |
Log In |
Log In |
| Medical Care Solutions Company Adjusted Operating Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Blood and Cell Technologies Company Adjusted Operating Profit |
Log In |
Log In |
Log In |
Log In |
| Blood and Cell Technologies Company Adjusted Operating Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Adjustments from Adjusted Operating Profit |
Log In |
Log In |
Log In |
Log In |
| Adjustments from Adjusted Operating Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Cardiac and Vascular Company Production Result |
Log In |
Log In |
Log In |
Log In |
| Cardiac and Vascular Company Production Result Growth |
Log In |
Log In |
Log In |
Log In |
| Medical Care Solutions Company Production Result |
Log In |
Log In |
Log In |
Log In |
| Medical Care Solutions Company Production Result Growth |
Log In |
Log In |
Log In |
Log In |
| Blood and Cell Technologies Company Production Result |
Log In |
Log In |
Log In |
Log In |
| Blood and Cell Technologies Company Production Result Growth |
Log In |
Log In |
Log In |
Log In |
| Total Production Result |
Log In |
Log In |
Log In |
Log In |
| Total Production Result Growth |
Log In |
Log In |
Log In |
Log In |